Navigation Links
Genta Receives Key Patent Related to Oral Gallium Compound G4544
Date:4/14/2008

roval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation;

-- the Company's ability to retain compliance with the NASDAQ's listing

qualifications; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2007 and its most recent quarterly report on Form 10-Q.


'/>"/>
SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Genta Incorporated Announces Third Quarter 2007 Financial Results
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Clinical Programs Featured at American Society of Hematology Meeting
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... --  TRU-D SmartUVC LLC, producers of the first ... that the General Services Administration has awarded the company ... This newly formed agreement will allow TRU-D SmartUVC ... including Department of Veteran Affairs and Department of Defense ... solutions for the Ebola effort in West ...
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a ... of epilepsy, today announced it will participate in the 33 ... 14, 2015, in San Francisco . ... Officer, will speak at 11:00 AM Pacific Time.  A live ... on the Investor Relations link on the Cyberonics home page ...
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2Insights into the Marketplace and Individual Market Growth 2
... 29, 2011 Reportlinker.com announces that a new market ... Orthopedics Markets http://www.reportlinker.com/p0368861/Orthopedics-Markets.html ... deals with the diagnosis and treatment of disorders and ... and ligaments associated with it. The orthopedics market has ...
... Pa. and MELBOURNE, Australia, March 28, 2011 ... ChemGenex Pharmaceuticals Limited (ASX: CXS) today jointly announced ... Ltd, intends to make a takeover bid for ... developing its lead product candidate, OMAPRO™, for the ...
Cached Medicine Technology:Reportlinker Adds Orthopedics Markets 2Reportlinker Adds Orthopedics Markets 3Reportlinker Adds Orthopedics Markets 4Reportlinker Adds Orthopedics Markets 5Reportlinker Adds Orthopedics Markets 6Reportlinker Adds Orthopedics Markets 7Reportlinker Adds Orthopedics Markets 8Reportlinker Adds Orthopedics Markets 9Reportlinker Adds Orthopedics Markets 10Reportlinker Adds Orthopedics Markets 11Reportlinker Adds Orthopedics Markets 12Reportlinker Adds Orthopedics Markets 13Reportlinker Adds Orthopedics Markets 14Reportlinker Adds Orthopedics Markets 15Reportlinker Adds Orthopedics Markets 16Reportlinker Adds Orthopedics Markets 17Reportlinker Adds Orthopedics Markets 18Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 2Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 3Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 4Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 5Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 6Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 7Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 8Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 9Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 10Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 11Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 12Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 13Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 14Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited 15
(Date:12/22/2014)... (HealthDay News) -- U.S. and state health officials are ... has killed at least four people and sickened 28 ... any commercially produced, prepackaged caramel apples until more information ... Prevention said in a news release. As of ... infected with the outbreak strains of the bacteria ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Explorys, the ... additions to its leadership team: Greg Yarrington as Vice ... Engineering, and Patrick Wells as Vice President of Solutions. ... add 80 new jobs in 2015 to support client ... of its platform-as-a-service offerings, and growth of its partner ...
(Date:12/22/2014)... 22, 2014 Pasadena sleep apnea ... for sleep apnea. Drowsy drivers are 15 times more ... are well-rested, and some experts believe that sleep-deprived drivers ... intoxicated drivers. Unfortunately, millions of Americans may be sleep-deprived ... of Sleep Medicine, about 18 million Americans have sleep ...
(Date:12/22/2014)... 2014 Christmas is days away, and last ... and easy solution that will please: the Sublime Gift ... from from $25 up to $350," says Kathy Heshelow, founder ... and a wide array of skin care products and Skin ... expiration dates. , Gift delivery past shipping deadlines, or ...
(Date:12/22/2014)... At the annual National ... in San Antonio, esteemed experts and thought leaders ... stand in the way of successful organizational performance: ... premier faculty development opportunity is made possible through ... is to assist nurse educators to advance to ...
Breaking Medicine News(10 mins):Health News:CDC Warns of Listeria Danger From Caramel Apples 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3
... Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat ... physicians another choice in their treatment options.At the 45th ... Clinical Oncology (ASCO), researchers from the Mayo ... of capecitabine, vinorelbine, and trastuzumab offers a treatment option ...
... pill used for nerve pain offers women relief from hot ... the 45th Annual Meeting of the American Society ... decreased hot flash severity and frequency about 20 percent more ... about the same benefit as gabapentin, an older, related drug, ...
... Patient Advocacy EffortsSAN DIEGO, May 18 The Coalition ... the American Thoracic Society,s (ATS) International conference in San ... meeting brings together the world,s leading pulmonary, critical care ... for a partner grant program with ATS that, to ...
... no more dangerous than regular flu , , MONDAY, May 18 ... to be no worse than seasonal flu, the death rate ... seen with seasonal flu, U.S. heath officials said Monday. ... [rate] is likely a little bit higher than seasonal influenza, ...
... Inc.,(OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a company ... China,("PRC"), today reported its financial results for the first quarter ... 2009 Highlights and Recent Developments:, -- Diluted ... $3.6 million, up 258% from first quarter 2008, ...
... RI It is time for states to suspend, ... they are incarcerated, say correctional health care experts from ... the Journal of General Internal Medicine . ... for prisoners, 90 percent of states have implemented policies ...
Cached Medicine News:Health News:Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer 2Health News:Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer 3Health News:Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes 2Health News:Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes 3Health News:Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes 4Health News:Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference 2Health News:Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference 3Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 2Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 3Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 4Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 5Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 6Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 7Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 8Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 9Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 10Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 11Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 12Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 13Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 2Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 3Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 4Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 5Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 6Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 7Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 8Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 9Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 10Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 11Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 12Health News:Filling the gap: The importance of Medicaid continuity for former inmates 2
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
Protects the eye from symptoms caused by "dry eye, medical conditions, drug reactions and environmental factors. Forms a moisture chamber over the eye area during rest....
... Medtronic Ophthalmics offers the most ... specialty Eraser Instruments for Cataract incision, ... and discrete coagulation is achieved with ... cellular necrosis. Straight eraser styles are ...
Medicine Products: